Aftab, Fareesa http://orcid.org/0000-0002-1202-1189
Rodriguez-Fuguet, Alice
Silva, Luis http://orcid.org/0000-0002-0178-5431
Kobayashi, Ikei S.
Sun, Jiao
Politi, Katerina
Levantini, Elena
Zhang, Wei
Kobayashi, Susumu S. http://orcid.org/0000-0003-2262-4001
Zhang, Wen Cai http://orcid.org/0000-0002-5274-527X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (1 DK097771)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA240257)
Article History
Received: 21 June 2022
Revised: 27 January 2023
Accepted: 1 February 2023
First Online: 21 February 2023
Competing interests
: KP reports grants and consulting fees from AstraZeneca; grants from Roche/Genentech and Boehringer Ingelheim; and consulting fees from Jannssen; and a patent for EGFR<sup>T790M</sup> mutation testing issued, licensed, and with royalties paid from Molecular Diagnostics/Memorial Sloan Kettering Cancer Center. No other potential conflicts of interest were disclosed.
: All tissues were obtained under written informed patient consent and were de-identified. Only de-identified human tumour samples implanted in immunodeficient mice were used to generate PDXs for Yale University. The procedures for patient samples and data collection were approved by Yale University Human Investigation Committee. All relevant ethical regulations were followed. The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.